BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14533836)

  • 1. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL; Norwood C; Stashower ME
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal melanonychia induced by capecitabine.
    Paravar T; Hymes SR
    Dermatol Online J; 2009 Oct; 15(10):11. PubMed ID: 19951629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 6. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
    Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
    Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
    [No Abstract]   [Full Text] [Related]  

  • 7. Onycholysis associated with capecitabine in patients with breast cancer.
    Hogeling M; Howard J; Kanigsberg N; Finkelstein H
    J Cutan Med Surg; 2008; 12(2):93-5. PubMed ID: 18346407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine induced cutaneous hyperpigmentation: report of a case.
    Pui JC; Meehan S; Moskovits T
    J Drugs Dermatol; 2002 Sep; 1(2):202-5. PubMed ID: 12847748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
    Tejera A; Bosch RJ; López N; Herrera E
    Actas Dermosifiliogr; 2006 Oct; 97(8):536-8. PubMed ID: 17067535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Tavares-Bello R
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
    [No Abstract]   [Full Text] [Related]  

  • 11. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and PPE syndrome: a case report.
    LoRusso PM
    Breast J; 2003; 9(1):64-5. PubMed ID: 12558679
    [No Abstract]   [Full Text] [Related]  

  • 13. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
    Sauter C; Saborowski A; Ockenfels HM
    Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand and foot syndrome secondary to capecitabine.
    Lal HS
    Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine induced inflammation of actinic keratoses.
    Krathen M; Treat J; James WD
    Dermatol Online J; 2007 Oct; 13(4):13. PubMed ID: 18319010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nail and periungual toxicity following capecitabine therapy.
    Vaccaro M; Barbuzza O; Guarneri F; Guarneri B
    Br J Clin Pharmacol; 2008 Aug; 66(2):325-6. PubMed ID: 18384441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.